| DESCRIPTION | Co. has identified a lead compound from a series of orally active small molecules that selectively inhibit or prevent the production of immunoglobulin epsilon (IgE) antibodies. It is our objective to produce an orally bioavailable product, with a unique mechanism of action, that will significantly prevent or reduce the signs and symptoms of allergic asthma and allergic rhinitis. |
| COMPANY | This data is not available for free |
|
Want more information ? Interested in the hidden information ? Click here and do your request. |